This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Craig, W. A.
Right arrow Articles by Andes, D. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Craig, W. A.
Right arrow Articles by Andes, D. R.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, October 2008, p. 3492-3496, Vol. 52, No. 10
0066-4804/08/$08.00+0     doi:10.1128/AAC.01273-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

In Vivo Pharmacodynamics of Ceftobiprole against Multiple Bacterial Pathogens in Murine Thigh and Lung Infection Models{triangledown}

W. A. Craig1,2* and D. R. Andes1

Department of Medicine, Section of Infectious Diseases, University of Wisconsin School of Medicine and Public Health,1 William S. Middleton Memorial Veterans Hospital, Madison, Wisconsin2

Received 1 October 2007/ Returned for modification 6 December 2007/ Accepted 24 July 2008

Ceftobiprole medocaril is the parenteral prodrug of ceftobiprole, a novel pyrrolidinone broad-spectrum cephalosporin with in vitro and in vivo bactericidal activities against methicillin-resistant Staphylococcus aureus (MRSA) and penicillin-resistant Streptococcus pneumoniae (PRSP). We have used murine thigh and lung infection models in neutropenic and normal mice to characterize the in vivo pharmacokinetic (PK)-pharmacodynamic (PD) activities of ceftobiprole against multiple strains of S. aureus (including MRSA), S. pneumoniae (including PRSP), and gram-negative bacilli. Serum levels of ceftobiprole following the administration of multiple doses were determined by a microbiological assay. In vivo bactericidal activities and postantibiotic effects (PAEs) of ceftobiprole against MRSA and PRSP strains were determined from serial CFU/thigh values following single doses of ceftobiprole (40 and 160 mg/kg of body weight). Dose fractionation studies were used to determine which PK-PD index correlated best with activity. Magnitudes of the PK-PD indices were calculated from MICs and PK parameters. A sigmoid dose-response model was used to estimate the dose (mg/kg/24 h) required to achieve a static and 2-log10 kill effects over 24 h. PK results showed area under the concentration-time curve/dose values of 1.8 to 2.8 and half-lives of 0.29 to 0.51 h. MICs ranged from 0.015 to 2 µg/ml. Ceftobiprole demonstrated time-dependent killing; its in vivo PAEs varied from 3.8 h to 4.8 h for MRSA and from 0 to 0.8 h for PRSP. The time above MIC (T > MIC) correlated best with efficacy for both MRSA and PRSP. The T > MIC values required for the static doses were significantly longer (P < 0.001) for Enterobacteriaceae (36 to 45%) than for S. aureus (14 to 28%) and S. pneumoniae (15 to 22%). The drug showed activities in the lung model similar to those in the thigh model. The presence of neutrophils significantly enhanced the activity of ceftobiprole against S. pneumoniae but only slightly against Klebsiella pneumoniae. Based on its PD profile, ceftobiprole is a promising new β-lactam agent with activity against gram-negative and gram-positive organisms including MRSA and PRSP.

* Corresponding author. Mailing address: William S. Middleton Memorial Veterans Hospital, 2500 Overlook Terrace, Madison, WI 53705. Phone: (608) 256-1901. Fax: (608) 265-8979. E-mail: wac{at}medicine.wisc.edu

{triangledown} Published ahead of print on 1 August 2008.

Antimicrobial Agents and Chemotherapy, October 2008, p. 3492-3496, Vol. 52, No. 10
0066-4804/08/$08.00+0     doi:10.1128/AAC.01273-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Zhanel, G. G., Voth, D., Nichol, K., Karlowsky, J. A., Noreddin, A. M., Hoban, D. J. (2009). Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model. J Antimicrob Chemother 64: 364-369 [Abstract] [Full Text]  
  • Louie, A., Fregeau, C., Liu, W., Kulawy, R., Drusano, G. L. (2009). Pharmacodynamics of Levofloxacin in a Murine Pneumonia Model of Pseudomonas aeruginosa Infection: Determination of Epithelial Lining Fluid Targets. Antimicrob. Agents Chemother. 53: 3325-3330 [Abstract] [Full Text]  
  • Rodvold, K. A., Nicolau, D. P., Lodise, T. P., Khashab, M., Noel, G. J., Kahn, J. B., Gotfried, M., Murray, S. A., Nicholson, S., Laohavaleeson, S., Tessier, P. R., Drusano, G. L. (2009). Identifying Exposure Targets for Treatment of Staphylococcal Pneumonia with Ceftobiprole. Antimicrob. Agents Chemother. 53: 3294-3301 [Abstract] [Full Text]  
  • Kimko, H., Xu, X., Nandy, P., Samtani, M. N., Strauss, R. S., Bagchi, P., Noel, G. J. (2009). Pharmacodynamic Profiling of Ceftobiprole for Treatment of Complicated Skin and Skin Structure Infections. Antimicrob. Agents Chemother. 53: 3371-3374 [Abstract] [Full Text]  
  • Barbour, A., Schmidt, S., Sabarinath, S. N., Grant, M., Seubert, C., Skee, D., Murthy, B., Derendorf, H. (2009). Soft-Tissue Penetration of Ceftobiprole in Healthy Volunteers Determined by In Vivo Microdialysis. Antimicrob. Agents Chemother. 53: 2773-2776 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»